


### A NOVEL ANTIPLATELET AGENT

**Clopiwas** (Clopidogrel bisulfate), a thienopyridine antiplatelet agent, is an adenosine diphosphate (ADP)-receptor antagonist.


**Clopiwas** is a selective and potent inhibitor of platelet aggregation. **Clopiwas** binds to the ADP receptor and blocks ADP-induced aggregation. Blocking ADP binding results in a coupled biochemical reaction that inhibits binding of fibrinogen to the GPIIb/IIIa receptor on the platelet surface. The end result is an irreversible modification of the platelet, rendering it unable to aggregate.

Clopidogrel inhibits platelet aggregation<sup>1</sup> - a key and early step in the thrombotic disease process.



### EFFECTIVE ANTIPLATELET THERAPY FOR A BROAD SPECTRUM OF PATIENTS

- PATIENTS AFTER RECENT MI OR RECENT STROKE
- PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE



*“Patients at increased risk included those with atherothrombotic disease such as transient ischaemic attacks or mild stroke, unstable angina, acute and remote myocardial infarction, and atherosclerotic peripheral arterial disease”.<sup>2</sup>*

*“Long term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing combined risk of ischaemic stroke, myocardial infarction, or vascular death”.<sup>3</sup>*

### SUPERIOR TO TICLOPIDINE

- **Six times more potent than Ticlopidine**
- **Achieves platelet inhibition more rapidly**
  - Inhibits 55% of platelets within 1 hour and 80% platelet within 5 hours (with loading dose)
  - Benefits of clopidogrel seen as early as 24 hours compared to 3 days with Ticlopidine
- **Once daily dosing**
- **Better side-effect profile**
  - Less incidence of neutropenia or thrombocytopenia
  - Lesser incidence with rash or diarrhoea
- **No changes in cholesterol levels**
  - Increase in cholesterol by 8-10% observed with ticlopidine
- **Lesser drug interactions**

1. Am J Med 1996; 101, 199-209  
 2. Lancet 1996; 348, 1329-1339  
 3. NEJM 2001; 345, 494-502

# Clopivas

Clopidogrel Tablets USP **75 mg**

# Cipla

## CIPLA – YOUR HEALTHCARE PARTNER SINCE 1935

Produced by CIPLA, a leading provider of pharmaceuticals.

### Key Facts about CIPLA.

- 25 manufacturing facilities approved by leading regulatory authorities including the FDA (USA), MHRA (U.K.) and TGA (Australia).
- Over 1000 Formulations and 150 Active Pharmaceutical Ingredients.
- Prequalified and Approved by the World Health Organisation (WHO) for supply to UN Agencies.
- The World's largest range of antiasthmatic aerosols and inhalation devices.
- The World's largest manufacturer of antiretroviral drugs and supplier to the Clinton Foundation AIDS/HIV Initiative.

## CIPLA RANKED NO. 10 IN THE ASIA BUSINESSWEEK 50

### The Asia BusinessWeek 50

The region's top-performing companies\*

	COMPANY	COUNTRY	BUSINESS
1	UNILEVER INDONESIA	Indonesia	CONSUMER PRODUCTS
2	HIGH TECH COMPUTER	Taiwan	COMPUTER HARDWARE
3	LION DIVERSIFIED HOLDINGS	Malaysia	RETAILING
4	SIEMENS (INDIA)	India	COMMUNICATIONS EQUIPMENT
5	PAKISTAN PETROLEUM	Pakistan	OIL & GAS
6	STERILITE INDUSTRIES	India	METALS & MINING
7	JARDINE MATHESON HOLDINGS	Hong Kong	FINANCIAL SERVICES
8	TELEKOMUNIKASI INDONESIA	Indonesia	TELECOMMUNICATIONS
9	KOT ADDU POWER (KAPCO)	Pakistan	ELECTRIC POWER
10	CIPLA	India	PHARMACEUTICALS
11	SPARX GROUP	Japan	ASSET MANAGEMENT
12	CHIYODA	Japan	CONSTRUCTION & ENGINEERING
13	MOTECH INDUSTRIES	Taiwan	ELECTRONIC EQUIPMENT
14	ESPRIT HOLDINGS	Hong Kong	APPAREL RETAILING
15	SHIMAO PROPERTY HOLDINGS	Hong Kong	REAL ESTATE

\*2007 Rankings; Based on average return of Capital and Sales Growth (over the previous 3 years).

#### Distributed by

Controlled Medications Ltd  
Unit 204, 2/F New Bright Building  
11 Sheung Yuet Road, Kowloon Bay  
Kowloon, Hong Kong  
Tel: (852) 2896 0889  
Fax: (852) 2898 9842

**conmed**  
Controlled Medications Ltd.  
康德行有限公司